Protective role of Purα to cisplatin

Cancer Biology and Therapy

Volumn 7, Issue 12, 2008, Pages 1926-1935

  Kaminski, Rafal ^a   Darbinyan, Armine ^a   Merabova, Nana ^a   Deshmane, Satish L ^a   White, Martyn K ^a   Khalili, Kamel ^a,b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Chemotherapy; Cisplatin; DNA damage; DNA repair; Pur alpha; Single stranded DNA binding protein

Indexed keywords

CISPLATIN; HISTONE H2AX; NUCLEIC ACID BINDING PROTEIN; PROTEIN PURALPHA; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; HYDROGEN PEROXIDE; PURA PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DNA FRAGMENTATION; DNA REPAIR; EMBRYO; GLIOBLASTOMA; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; CELL CYCLE; CELL SURVIVAL; CLONOGENIC ASSAY; DNA REPLICATION; DRUG EFFECT; FIBROBLAST; GENETICS; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CELL CYCLE; CELL SURVIVAL; CISPLATIN; COLONY-FORMING UNITS ASSAY; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DNA-BINDING PROTEINS; FIBROBLASTS; GLIOBLASTOMA; HUMANS; HYDROGEN PEROXIDE; MICE; NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 58149133619     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.12.6938     Document Type: Article

References (44)

1. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7:573-84.
2. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22:7265-79.
3. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005; 4:307-20.
4. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008; 8:193-204.
5. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007; 63:12-31.
6. Köberle B, Grimaldi KA, Sunters A, Hartley JA, Kelland LR, Masters JR. DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int J Cancer 1997; 70:551-5.
7. Rosell R, Taron M, Barnadas A, Scagliotti G, Sarries C, Roig B. Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer. Cancer 2003; 10:297-305.
8. Bergoglio V, Canitrot Y, Hogarth L, Minto L, Howell SB, Cazaux C, Hoffmann JS. Enhanced expression and activity of DNA polymerase beta in human ovarian tumor cells: impact on sensitivity towards antitumor agents. Oncogene 2001; 20:6181-7.
9. Xu ZY, Loignon M, Han FY, Panasci L, Aloyz R. Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis. J Pharmacol Exp Ther 2005; 314:495-505.
10. Ali-Osman F, Berger MS, Rajagopal S, Spence A, Livingston RB. Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells. Cancer Res 1993; 53:5663-8.
11. Wang H, Wang M, Reiss K, Darbinian-Sarkissian N, Johnson EM, Iliakis G, Amini S, Khalili K, Rappaport J. Evidence for the involvement of Puralpha in response to DNA replication stress. Cancer Biol Ther 2007; 6:596-602.
12. Wang H, White MK, Kaminski R, Darbinian N, Johnson EM, Amini S, Khalili K, Rappaport J. Role of Purα in the modulation of homologous recombination-directed DNA repair by HIV-1 Tat. Anticancer Res 2008; 28:1441-8.
13. Haas S, Gordon J, Khalili K. A developmentally regulated DNA-binding protein from mouse brain stimulates myelin basic protein gene expression. Mol Cell Biol 1993; 13:3103-12.
14. Haas S, Thatikunta P, Steplewski A, Johnson EM, Khalili K, Amini S. A 39-kD DNA-binding protein from mouse brain stimulates transcription of myelin basic protein gene in oligodendrocytic cells. J Cell Biol 1995; 130:1171-9.
15. Bergemann AD, Johnson EM. The HeLa Pur factor binds single-stranded DNA at a specific element conserved in gene flanking regions and origins of DNA replication. Mol Cell Biol 1992; 12:1257-65.
16. Bergemann AD, Ma ZW, Johnson EM. Sequence of cDNA comprising the human pur gene and sequence-specific single-stranded DNA-binding properties of the encoded protein. Mol Cel. Biol 1992; 12:5673-82.
17. Ma ZW, Bergemann AD, Johnson EM. Conservation in human and mouse Puralpha of a motif common to several proteins involved in initiation of DNA replication. Gene 1994; 149:311-4.
18. Liu H, Johnson EM. Distinct proteins encoded by alternative transcripts of the PURG gene, located contrapodal to WRN on chromosome 8, determined by differential termination/polyadenylation. Nucleic Acids Res 2002; 30:2417-26.
19. Johnson EM. The Pur protein family: clues to function from recent studies on cancer and AIDS. Anticancer Res 2003; 23:2093-100.
20. Gallia GL, Johnson EM, Khalili K. Puralpha: a multifunctional single-stranded DNA- and RNA-binding protein. Nucleic Acids Res 2000; 28:3197-205.
21. Kanai Y, Dohmae N, Hirokawa N. Kinesin transports RNA: isolation and characterization of an RNA-transporting granule. Neuron 2004; 43:513-25.
22. Johnson EM, Kinoshita Y, Weinreb DB, Wortman MJ, Simon R, Khalili K, Winckler B, Gordon J. Role of Puralpha in targeting mRNA to sites of translation in hippocampal neuronal dendrites. J Neurosci Res 2006; 83:929-43.
23. Kaminski R, Darbinian N, Sawaya BE, Slonina D, Amini S, Johnson EM, Rappaport J, Khalili K, Darbinyan A. Puralpha as a cellular co-factor of Rev/RRE-mediated expression of HIV-1 intron-containing mRNA. J Cell Biochem 2008; 103:1231-45.
24. Johnson EM, Chen PL, Krachmarov CP, Barr SM, Kanovsky M, Ma ZW, Lee WH. Association of human Puralpha with the retinoblastoma protein, Rb, regulates binding to the single-stranded DNA Pur alpha recognition element. J Biol Chem1995; 270:24352-60.
25. Darbinian N, Gallia GL, Kundu M, Shcherbik N, Tretiakova A, Giordano A, Khalili K. Association of Puralpha and E2F-1 suppresses transcriptional activity of E2F-1. Oncogene 1999; 18:6398-402.
26. Darbinian N, White MK, Khalili K. Regulation of the Pur-alpha promoter by E2F-1. J Cell Biochem 2006; 99:1052-63.
27. Tretiakova A, Steplewski A, Johnson EM, Khalili K, Amini S. Regulation of myelin basic protein gene transcription by Sp1 and Puralpha: evidence for association of Sp1 and Puralpha in brain. J Cell Physiol 1999; 181:160-8.
28. Safak M, Gallia GL, Khalili K. Reciprocal interaction between two cellular proteins, Puralpha and YB-1, modulates transcriptional activity of JCVCY in glial cells. Mol Cell Biol 1999; 19:2712-23.
29. Itoh H, Wortman MJ, Kanovsky M, Uson RR, Gordon RE, Alfano N, Johnson EM. Alterations in Pur(alpha) levels and intracellular localization in the CV-1 cell cycle. Cell Growth Differ 1998; 9:651-65.
30. Stacey DW, Hitomi M, Kanovsky M, Gan L, Johnson EM. Cell cycle arrest and morphological alterations following microinjection of NIH3T3 cells with Puralpha. Oncogene 1999; 18:4254-61.
31. Barr SM, Johnson EM. Ras-induced colony formation and anchorage-independent growth inhibited by elevated expression of Puralpha in NIH3T3 cells. J Cell Biochem 2001; 81:621-38.
32. Darbinian N, Gallia GL, King J, Del Valle L, Johnson EM, Khalili K. Growth inhibition of glioblastoma cells by human Pur(alpha). J Cell Physiol 2001; 189:334-40.
33. Bruchova H, Borovanova T, Klamova H, Brdicka R. Gene expression profiling in chronic myeloid leukemia patients treated with hydroxyurea. Leuk Lymphoma 2002; 43:1289-95.
34. Lezon-Geyda K, Najfeld V, Johnson EM. Deletions of PURA, at 5q31, and PURB, at 7p13, in myelodysplastic syndrome and progression to acute myelogenous leukemia. Leukemia 2001; 15:954-62.
35. Khalili K, Del Valle L, Muralidharan V, Gault WJ, Darbinian N, Otte J, Meier E, Johnson EM, Daniel DC, Kinoshita Y, Amini S, Gordon J. Puralpha is essential for postnatal brain development and developmentally coupled cellular proliferation as revealed by genetic inactivation in the mouse. Mol Cell Biol 2003; 23:6857-75.
36. Cenni B, Kim HK, Bubley GJ, Aebi S, Fink D, Teicher BA, Howell SB, Christen RD. Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin. Br J Cancer 1999; 80:699-704.
37. Merabova N, Kaniowska D, Kaminski R, Deshmane SL, White MK, Amini S, Darbinyan A, Khalili K. JC virus agnoprotein inhibits in vitro differentiation of oligodendrocytes and promotes apoptosis. J Virol 2008; 82:1558-69.
38. Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988; 175:184-91.
39. Speit GH, Hartmann A. The comet assay (single-cell gel test). A sensitive genotoxicity test for the detection of DNA damage and repair. Methods Mol Biol 1999; 113:203-12.
40. Olive PL, Banath JP, Durand RE. Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "comet" assay. Radiat Res 1990; 122:86-94.
41. Baumann P, West SC. DNA end-joining catalyzed by human cell-free extracts. Proc Natl Acad Sci USA 1998; 95:14066-70.
42. Darbinyan A, Siddiqui KM, Slonina D, Darbinian N, Amini S, White MK, Khalili K. Role of JC virus agnoprotein in DNA repair. J Virol 2004; 78:8593-600.
43. Darbinyan A, White MK, Akan S, Radhakrishnan S, Del Valle L, Amini S, Khalili K. Alterations of DNA damage repair pathways resulting from JCV infection. Virology 2007; 364:73-86.
44. Darbinian N, White MK, Gallia GL, Amini S, Rappaport J, Khalili K. Interaction between the Pura and E2F-1 transcription factors. Anticancer Res 2004; 24:2585-94.